BILL Holdings (BILL) Q3 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Karen Sansot - VP of Investor RelationsRené Lacerte - Founder, CEO & Chairperson of the BoardJohn Rettig - President & CFOIan Black - Equity Research AssociateDarrin Peller - Managing DirectorAlex Markgraff - Vice President - Equity ResearchAdib Choudhury - Senior Equity Research Associate Conference Call Participants Tien-tsin Huang - Senior AnalystKen Suchoski - Equity Research AnalystChris Quintero - AnalystAndrew Sc ...

HireQuest (HQI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Jennifer Belodeau - Vice PresidentRick Hermanns - President and Chief Executive OfficerSteve Crane - CFOKevin Steinke - Managing Director Operator Good afternoon, everyone, and thank you for participating in today's conference call to discuss HireQuest's financial results for the First Quarter ended 03/31/2025. At this time, all participants are in a listen only mode. A question and answer session will follow the formal pres ...

Profound Medical (PROF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsRashed Dewan - CFOMathieu Burtnyk - PresidentTom Tamberrino - Chief Commercial OfficerArun Menawat - Chairman & CEOBen Haynor - Managing DirectorJohn McAulay - AVPScott McAuley - Head of Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter twenty tw ...

Financial Data and Key Metrics Changes - The company recognized $400,000 in revenue during Q1 2025, down from $600,000 in Q1 2024, with revenue being non-cash based on amortization of payments from a licensing arrangement [40] - Research and development (R&D) expenses increased by 43% to $76.2 million in Q1 2025 compared to the same period in 2024, primarily due to additional personnel and higher manufacturing costs [40] - Selling, general, and administrative (SG&A) expenses rose by 71% to $35.5 million in Q1 2025, driven by growth to support ongoing programs and the planned commercial launch of paltusotine [41] - Cash used in operations for Q1 2025 was $88.5 million, compared to $52.9 million in Q1 2024, with expectations of cash used in operations for 2025 between $340 million and $380 million [42] - The company ended Q1 2025 with approximately $1.3 billion in cash, cash equivalents, and investments, expected to fund operations into 2029 [42] Business Line Data and Key Metrics Changes - The company is focused on the anticipated commercial launch of paltusotine, which is expected to significantly improve treatment for patients with acromegaly [8][10] - The pipeline includes two late-stage candidates and three additional candidates in preclinical studies, indicating a robust development strategy [8] Market Data and Key Metrics Changes - The company is preparing for the launch of paltusotine in the U.S. and has engaged with payers, receiving positive feedback regarding the product's value proposition [18][23] - The anticipated launch strategy includes educating healthcare professionals and patients, with a focus on addressing the unmet needs in acromegaly treatment [12][16] Company Strategy and Development Direction - The company aims to become a fully integrated global commercial organization, with a strong commitment to patient care and scientific innovation [8] - The strategic focus includes advancing a robust pipeline while preparing for the commercial launch of paltusotine, which is seen as a pivotal milestone [10][24] - The company is also exploring opportunities in the CAH (congenital adrenal hyperplasia) market with the development of adomelna [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory engagement with the FDA and the progress of clinical development activities [10][24] - The company remains optimistic about the potential uptake of paltusotine during the early launch phase, anticipating major interest from healthcare providers and patients [23] Other Important Information - The company has welcomed a new CFO, Toby Schulke, who brings extensive experience in transitioning R&D-focused companies into commercial organizations [9] - The company has launched the Kineticare patient support service platform to assist patients throughout their treatment journey [16][17] Q&A Session Summary Question: Can you discuss the powering of your primary endpoint and any data from cohort four? - Management indicated that the study is highly powered to detect significant differences between treatment and placebo groups, and cohort four is currently enrolling with no data available yet [46][48] Question: Is the CALM CAH study design approved by the FDA for registration? - The protocol was developed with input from the FDA, and the company expects to discuss the indication statement based on the data collected [51][54] Question: What is the rationale for testing the primary endpoint at a single time point? - Management explained that responder analyses are typically conducted at single points in time due to variability in biochemical markers, and they are confident in achieving the endpoint [57][58] Question: What is the rationale for morning versus evening dosing in cohort four? - The company aims to explore the convenience of morning dosing while considering the diurnal rhythm of CAH patients [61][62] Question: How is the launch strategy different in Europe compared to the U.S.? - The European markets are more concentrated in terms of patient populations, and the company is preparing for a launch in Germany while considering Brazil for expansion [64][68]

Aqua Metals (AQMS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Bob Meyers - Investor RelationsSteve Cotton - CEO, President & DirectorJudd Merrill - CFOEric West - CFO Conference Call Participants Mickey Legg - Equity Research Analyst Bob Meyers Any forward looking statements. The company does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. As a r ...

TELA Bio (TELA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalAntony Koblish - Co-Founder, CEO & PresidentRoberto Cuca - CFO & COOMichaela Smith - Equity Research Associate Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Sarcone - AnalystDavid Turkaly - Research Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter twenty twenty five Earnings Conference Call. At this time, all participants a ...

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Bernie Hertel - Head IR & CommunicationsPunit Dhillon - President, CEO, Secretary & DirectorChris Twitty - Chief Scientific OfficerKaitlyn Arsenault - Chief Financial OfficerPuneet Arora - Chief Medical Officer Conference Call Participants None - AnalystJay Olson - Managing Director & Senior Analyst - BiotechnologyAlbert Lowe - Senior Research AnalystEdward Tenthoff - Sr. Research AnalystKristen Kluska - AnalystAndy H ...

Financial Data and Key Metrics Changes - First quarter revenue for 2025 was $41.5 million, a decrease of 7.6% compared to the first quarter of 2024, primarily due to weakness in instrument sales in the U.S. and EMEA regions [9][26] - Service revenue increased by 24% year-over-year, reaching $13.3 million, driven by the expansion of the instrument installed base and active usage [9][27] - GAAP gross profit was $20.2 million, a decrease of 12% from $23 million in the prior year, with a GAAP gross margin of 49% compared to 51% a year ago [28][29] - Adjusted EBITDA loss was $3.3 million for the first quarter, compared to a loss of $0.7 million in Q1 of the previous year [31] Business Line Data and Key Metrics Changes - Product revenue, which includes instruments and reagents, decreased by 18% compared to Q1 of 2024, primarily due to a weaker instrument market in the U.S. and EMEA [26] - Aurora cell sorter revenue grew by 15% year-over-year, while Northern Lights revenue increased by 6% year-over-year in the first quarter [18] - Trailing twelve-month recurring revenue grew 17% year-over-year, representing 31% of total revenue in the first quarter, up from 26% a year ago [21][58] Market Data and Key Metrics Changes - Total revenue in the Asia Pacific and the rest of the world regions was $11.4 million, up 35.6% year-over-year, driven by strong demand in China [12][27] - U.S. and EMEA revenue declined by 13% and 24% respectively, due to lower instrument sales influenced by academic funding uncertainties and government budget pressures [27] Company Strategy and Development Direction - The company aims to solidify its position as a market leader in cell analysis solutions by expanding its product pipeline and investing in service teams [34] - The strategy includes region-for-region manufacturing to mitigate tariff impacts and enhance supply chain resilience [39][40] - The company is focused on growing its reagent business and expanding its installed base to drive recurring revenue growth [21][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning despite macroeconomic challenges, noting that over 50% of revenue comes from outside the U.S. [13][47] - The revised full-year 2025 revenue outlook is projected to be between $196 million and $210 million, reflecting a growth range of -2% to +5% compared to 2024 [32] - Management anticipates that uncertainties in funding will impact instrument sales, but service and reagent revenues are expected to continue growing [48][57] Other Important Information - The company has established manufacturing operations in the U.S., China, and Singapore to optimize product flows and enhance supply chain resilience [14] - The installed base of instruments increased by 115 units in the first quarter, bringing the total to 3,149 units [15] Q&A Session Summary Question: Impact of tariffs on gross margin - Management indicated that tariffs would have a limited impact on gross margin, estimated between 1% to 3%, and that gross margins are expected to improve as revenues increase in the following quarters [37][42] Question: Academic government end market outlook - Management acknowledged the uncertainties in university funding and indicated that these factors were included in the revised guidance, noting that over 50% of revenue is generated outside the U.S. [45][47] Question: Growth drivers for AURORA sales - Management highlighted that the growth in AURORA sales is driven by the alignment of their sorter and analyzer technologies, which are well-received by both academic and industry users [51][52] Question: R&D spending focus - Management confirmed that R&D spending remains between 15% to 20% of revenue, with a focus on imaging technologies for new product innovation [61][62] Question: Share repurchase versus M&A - Management stated that they plan to continue both share repurchases and have capital available for M&A, indicating a balanced approach to capital allocation [65]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $99.9 million, more than doubled year over year, and was in line with guidance of $94 million to $104 million [25][35] - Non-GAAP gross margin was 30.7%, above the guidance range of 29% to 30.5%, and up from 28.9% in Q4 2024 [28][29] - Non-GAAP net loss for Q1 was $0.9 million or $0.02 per share, compared to a loss of $12 million or $0.31 per share in Q1 2024 [30] Business Line Data and Key Metrics Changes - CATV segment revenue was $64.5 million, up more than six times year over year and increased 24% sequentially, driven by 1.8 GHz amplifier shipments [25][26] - Data center products revenue was $32 million, up 11% year over year but down 28% sequentially due to inventory digestion [25][26] - Telecom segment revenue was $2.9 million, up 29% year over year but down 17% sequentially [27] Market Data and Key Metrics Changes - 70.8% of data center revenue came from 100 Gbps products, with 10% from 200 Gbps and 400 Gbps products, and 10% from 40 Gbps products [26] - The top 10 customers represented 97% of revenue, with one customer in CATV contributing 64% and another in data center contributing 27% [28] Company Strategy and Development Direction - The company is focused on expanding production capacity for 800 Gbps and higher transceivers, with plans to reach approximately 40,000 transceivers per month by the end of 2025 [13][24] - The company aims to return non-GAAP gross margin to around 40% in the long term, driven by manufacturing efficiencies and improved product mix [29] - The company is committed to onshoring production to meet customer demand for domestic manufacturing, particularly in light of tariff concerns [15][16] Management's Comments on Operating Environment and Future Outlook - Management noted strong demand in the CATV market and positive long-term growth trends in both CATV and data center markets [12][18] - The company expects a modest sequential decrease in CATV revenue in Q2 due to retooling for Motorola-style amplifiers [35] - Management remains vigilant regarding tariff impacts but does not expect significant effects in Q2 based on current information [12] Other Important Information - The company ended Q1 with $66.8 million in cash and equivalents, down from $79.1 million at the end of Q4 2024 [32] - Capital expenditures for the year are expected to be between $120 million and $150 million, with a focus on expanding production capacity [34] Q&A Session Summary Question: What is the status of channel inventory for cable TV products? - Management has good knowledge of inventory levels and is intentionally building inventory in anticipation of revenue ramp due to tariff concerns [37][38] Question: Can you clarify the retooling to Motorola-style amplifiers? - The company is shifting production to Motorola-style amplifiers and expects to have significant inventory of both products by June [52] Question: What is the long-term market outlook for 800 Gbps products? - The market for 800 Gbps is expected to grow significantly, with the company aiming to be a major supplier for Amazon and other hyperscale customers [55][76] Question: What is the margin differential between cable TV and data center transceivers? - Cable TV products currently have margins that are 300 to 600 basis points higher than data center products [81] Question: What is the qualification status for 800 Gbps products? - The company is in the final qualification phase for several customers and expects to ramp production significantly in the second half of the year [83][85]

Xponential Fitness (XPOF) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Patricia Nir - Senior Vice PresidentMark King - CEO & DirectorJohn Meloun - Chief Financial OfficerRandal Konik - Managing DirectorJoe Altobello - Managing DirectorChris O'cull - Managing DirectorRichard Magnusen - Senior Research AssociateJohn-Paul Wollam - Equity Research AssociateLogan Hennen - Equity Research Associate Conference Call Participants John Heinbockel - Senior MD & Equity Research AnalystJonathan Ko ...